<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748240</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-Aza-Vor 2012-001401-25</org_study_id>
    <nct_id>NCT01748240</nct_id>
  </id_info>
  <brief_title>Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure</brief_title>
  <acronym>GFM-AZA-VOR</acronym>
  <official_title>Addition of Suberoylanilide Hydroxamic Acid (Vorinostat) to Azacitidine in Patients With Higher Risk Myelodysplastic Syndromes (MDS): a Phase II add-on Study in Patients With Azacitidine Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Azacytidine (AZA) is the current standard of care for frontline patient treated with
      high-risk MDS and is clinically active in all type of MDS, however, 50% of the patients will
      never respond. Vorinostat is an orally available HDAC inhibitor with clinical activity in MDS
      and proven in vitro synergy with AZA. Patient treated upfront with a combination of this
      agents have shown more responses based on phase I/II data. In the present study, we will use
      the combination of these two drugs to try to create a synergetic effect and generate a
      response for patients who experienced treatment failure after AZA.

      All eligible patients will be treated with Azacitidine and oral vorinostat for 6 cycles of 28
      days. Study Design
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two
      times daily for 7 days as outlined in table 1.1. AZA will be administered SC at 75 mg/m2/day
      x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed
      before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.

      Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting
      on day 3.

      Patients will receive 6 cycles unless progression is documented. Patients with a complete
      remission (CR), partial remission (PR), or hematological improvement (HI), will be treated
      until progression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inefficiency
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 month</time_frame>
    <description>All eligible patients will be treated with Azacitidine and oral vorinostat for 6 cycles of 28 days.
The response rate (CR, PR, HI or marrow CR) will be evaluated after six cycles, according to IWG 2006.
In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Complete Response (CR): Bone marrow: less than 5% myeloblasts with Peripheral blood: HI responses).
Partial remission (RP): Bone marrow blasts decreased by at least 50% but still more than 5% with Peripheral blood: HI responses).
Marrow CR:Bone marrow: maximum of 5% myeloblasts and decrease by at least 50% over pretreatment
HI (hematologic improvement)
Erythroid response: Hgb increase at least by 1.5 g/dL
Platelet response: Increase from less than 20x109/L to more than 20x109/L and by at least 100%
Neutrophil response: At least 100% increase and an absolute increase of at least 0.5x109/L</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Azacitidine and oral vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.
Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine and oral vorinostat</intervention_name>
    <description>In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.</description>
    <arm_group_label>Azacitidine and oral vorinostat</arm_group_label>
    <other_name>Suberoylanilide Hydroxamic acid (Vorinostat)</other_name>
    <other_name>Azacitidine (Vidaza)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myelodysplastic syndrome (WHO and FAB classified) including: RA, RARS, RCMD, RCMD-RS
             RAEB , RAEB-t and CMML with WBC &lt; 13000/mm3)

          -  IPSS score 1.5 or higher (IPSS intermediate-2 and high risk categories) at the
             beginning of azacitidine,

          -  Absence of response (CR, PR, marrow CR or HI according to IWG 2006) after a minimum of
             6 cycles of azacitidine single agent at 75 mg/m²/d for 7 days per cycle. Patients with
             a previous dose reduction of AZA may be eligible if the maximum tolerated dose was
             equal to or above 350mg/m2/cycle (i.e. 50 mg/m²/d for 7 days or 75mg/m2/d for 5 days).

          -  Age more or egal to 18 years

          -  ECOG performance status ≤ 2 (cf. appendix 2);

          -  Patient must have adequate organ function as indicated by the following laboratory
             values

        Renal Serum creatinine or calculated creatinine clearancea &lt; 2 mg/dl OR ≥ 60 mL/min for
        patients with creatinine levels &gt; 1.5 X institutional ULN Hepatic

        Serum total bilirubin ≤ 2.5 X ULN OR direct bilirubin ≤ ULN for patients with total
        bilirubin levels ≥ 2 mg/dL.

        AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN Alkaline Phosphatase ≤ 5 X ULN If &gt; 2.5 X ULN,
        then liver fraction should be ≤ 2.5 X ULN a Creatinine clearance should be calculated per
        institutional standard.

          -  Patient is known to not be refractory to platelet transfusions.

          -  Patient ineligible for allogeneic hematopoietic stem cell transplantation at the time
             of inclusion in the study

          -  Adherence to the study visit schedule;

          -  Women of childbearing potential must:

        Agree to use effective contraception without interruption throughout the study and for a
        further 3 months after the end of treatment;

        - Men must: Agree to not conceive during the treatment and to use effective contraception
        during the treatment period (including periods of dose reduction or temporary suspension)
        and for a further 3 months after the end of treatment if their partner is of childbearing
        potential.

        Agree to learn about the procedures for preservation of sperm.

        Exclusion Criteria:

          -  Patient had prior treatment with an HDAC inhibitor (e.g., depsipeptide or NSC-630176,
             MS 275, LAQ-824, PXD-101, LBH589, MGCD0103, CRA024781, etc). Patients who have
             received compounds with HDAC inhibitor-like activity, such as valproic acid, as
             anti-tumor therapy should not enroll in this study. Patients who have received such
             compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a
             30-day washout period.

          -  Severe infection or any other uncontrolled severe condition.

          -  Last dose of AZA was given more than 3 months before entering the trial.

          -  Patient already enrolled in another therapeutic trial of an investigational drug

          -  HIV infection or active hepatitis B or C.

          -  Patient has a known allergy or hypersensitivity to any component of vorinostat or
             azacitidine.

          -  Active cancer, or cancer during the year prior to trial entry other than basal cell
             carcinoma or carcinoma in situ of the cervix or breast.

          -  Less than 30 days since prior treatment with growth factors (EPO, G-CSF) or
             non-cytotoxic agents (including low-dose oral chemotherapy); in the event of prior
             treatment with cytotoxic or demethylating agents, an interval of 3 months is required;

          -  Patient is on any systemic steroids that have not been stabilized to the equivalent of
             ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.

          -  Patients with clinical evidence of CNS leukemia.

          -  Patient has a history of GI surgery or other procedures that might interfere with the
             absorption or swallowing of the study drugs.

          -  Women who are or could become pregnant, or who are currently breastfeeding

          -  Patient eligible for allotransplantation at the time of inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Prebet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité d'Hématologie-Institut Paoli Calmettes,Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Fenaux, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Saint Louis, hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de la côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le mans</name>
      <address>
        <city>Le mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPC-Unité d'Hématologie 3</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHU Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis - AP-HP, Hematology Dpt</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin-Hematology</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Haut-Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan-Medecine interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital PURPAN, Service d'Hématologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valence</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>November 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2018</results_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azacitidine and Oral Vorinostat</title>
          <description>Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.
Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.
Azacitidine and oral vorinostat: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azacitidine and Oral Vorinostat</title>
          <description>Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.
Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.
Azacitidine and oral vorinostat: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="43" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>All eligible patients will be treated with Azacitidine and oral vorinostat for 6 cycles of 28 days.
The response rate (CR, PR, HI or marrow CR) will be evaluated after six cycles, according to IWG 2006.
In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Complete Response (CR): Bone marrow: less than 5% myeloblasts with Peripheral blood: HI responses).
Partial remission (RP): Bone marrow blasts decreased by at least 50% but still more than 5% with Peripheral blood: HI responses).
Marrow CR:Bone marrow: maximum of 5% myeloblasts and decrease by at least 50% over pretreatment
HI (hematologic improvement)
Erythroid response: Hgb increase at least by 1.5 g/dL
Platelet response: Increase from less than 20x109/L to more than 20x109/L and by at least 100%
Neutrophil response: At least 100% increase and an absolute increase of at least 0.5x109/L</description>
        <time_frame>6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azacitidine and Oral Vorinostat</title>
            <description>Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.
Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.
Azacitidine and oral vorinostat: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>All eligible patients will be treated with Azacitidine and oral vorinostat for 6 cycles of 28 days.
The response rate (CR, PR, HI or marrow CR) will be evaluated after six cycles, according to IWG 2006.
In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Complete Response (CR): Bone marrow: less than 5% myeloblasts with Peripheral blood: HI responses).
Partial remission (RP): Bone marrow blasts decreased by at least 50% but still more than 5% with Peripheral blood: HI responses).
Marrow CR:Bone marrow: maximum of 5% myeloblasts and decrease by at least 50% over pretreatment
HI (hematologic improvement)
Erythroid response: Hgb increase at least by 1.5 g/dL
Platelet response: Increase from less than 20x109/L to more than 20x109/L and by at least 100%
Neutrophil response: At least 100% increase and an absolute increase of at least 0.5x109/L</description>
          <units>percentage of response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Azacitidine and Oral Vorinostat</title>
          <description>Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.
Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3.
Azacitidine and oral vorinostat: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>patients develloping diarrhea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea 3/21 (14.28)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>cosntipation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>undernutrition</sub_title>
                <description>patients presented the undernutrition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Groupe Francophone des Myelodysplasies</name_or_title>
      <organization>academic group</organization>
      <phone>+ 33 (0)1 71 20 70 59</phone>
      <email>fatiha.chermat@aphp.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

